United Therapeutics’ (UTHR) “Outperform” Rating Reiterated at Wedbush

Wedbush reiterated their outperform rating on shares of United Therapeutics (NASDAQ:UTHRGet Rating) in a research note released on Monday, Stock Target Advisor reports. They currently have a $263.00 price target on the biotechnology company’s stock.

Other analysts also recently issued reports about the company. JPMorgan Chase & Co. upped their price objective on United Therapeutics from $225.00 to $238.00 in a report on Tuesday, May 24th. StockNews.com upgraded United Therapeutics from a buy rating to a strong-buy rating in a report on Friday, September 9th. Credit Suisse Group increased their price target on United Therapeutics from $219.00 to $247.00 and gave the company an outperform rating in a report on Tuesday, May 24th. Jefferies Financial Group increased their price target on United Therapeutics from $223.00 to $245.00 in a report on Tuesday, May 24th. Finally, HC Wainwright increased their price target on United Therapeutics from $248.00 to $255.00 and gave the company a buy rating in a report on Tuesday, May 24th. One research analyst has rated the stock with a hold rating and six have assigned a buy rating to the stock. According to data from MarketBeat, the company currently has a consensus rating of Moderate Buy and an average price target of $250.14.

United Therapeutics Trading Down 0.6 %

Shares of UTHR opened at $216.89 on Monday. The company has a market capitalization of $9.87 billion, a PE ratio of 16.42, a price-to-earnings-growth ratio of 4.19 and a beta of 0.54. The company has a debt-to-equity ratio of 0.19, a quick ratio of 7.83 and a current ratio of 8.10. The stock has a fifty day moving average of $224.44 and a two-hundred day moving average of $209.12. United Therapeutics has a fifty-two week low of $158.38 and a fifty-two week high of $245.48.

United Therapeutics (NASDAQ:UTHRGet Rating) last released its quarterly earnings data on Wednesday, August 3rd. The biotechnology company reported $2.41 EPS for the quarter, missing analysts’ consensus estimates of $4.10 by ($1.69). The firm had revenue of $466.90 million for the quarter, compared to analyst estimates of $461.06 million. United Therapeutics had a return on equity of 15.50% and a net margin of 35.27%. The company’s quarterly revenue was up 4.6% on a year-over-year basis. During the same quarter in the previous year, the company earned $3.65 earnings per share. As a group, analysts forecast that United Therapeutics will post 15.21 EPS for the current year.

Insider Buying and Selling at United Therapeutics

In other United Therapeutics news, EVP Paul A. Mahon sold 6,000 shares of the company’s stock in a transaction dated Thursday, July 7th. The shares were sold at an average price of $242.04, for a total value of $1,452,240.00. Following the completion of the transaction, the executive vice president now directly owns 36,397 shares of the company’s stock, valued at approximately $8,809,529.88. The transaction was disclosed in a filing with the SEC, which is accessible through this link. In other United Therapeutics news, EVP Paul A. Mahon sold 6,000 shares of the company’s stock in a transaction dated Thursday, July 7th. The shares were sold at an average price of $242.04, for a total value of $1,452,240.00. Following the completion of the transaction, the executive vice president now directly owns 36,397 shares of the company’s stock, valued at approximately $8,809,529.88. The transaction was disclosed in a filing with the SEC, which is accessible through this link. Also, EVP Paul A. Mahon sold 4,552 shares of the company’s stock in a transaction dated Thursday, August 4th. The shares were sold at an average price of $225.81, for a total transaction of $1,027,887.12. Following the completion of the transaction, the executive vice president now directly owns 36,397 shares of the company’s stock, valued at $8,218,806.57. The disclosure for this sale can be found here. Insiders sold a total of 27,212 shares of company stock valued at $6,330,244 in the last ninety days. Insiders own 12.40% of the company’s stock.

Hedge Funds Weigh In On United Therapeutics

Large investors have recently modified their holdings of the stock. Charter Oak Capital Management LLC bought a new position in shares of United Therapeutics during the second quarter worth about $25,000. Cullen Frost Bankers Inc. bought a new position in shares of United Therapeutics during the second quarter worth about $26,000. Ronald Blue Trust Inc. bought a new position in shares of United Therapeutics during the second quarter worth about $28,000. Hallmark Capital Management Inc. bought a new position in shares of United Therapeutics during the second quarter worth about $33,000. Finally, MCF Advisors LLC bought a new position in shares of United Therapeutics during the first quarter worth about $34,000. Institutional investors own 95.57% of the company’s stock.

About United Therapeutics

(Get Rating)

United Therapeutics Corporation, a biotechnology company, engages in the development and commercialization of products to address the unmet medical needs of patients with chronic and life-threatening diseases in the United States and internationally. Its commercial therapies include Remodulin to treat patients with pulmonary arterial hypertension (PAH) to diminish symptoms associated with exercise; Tyvaso, an inhaled formulation of prostacyclin analogue treprostinil to enhance the exercise ability in PAH patients and pulmonary hypertension associated with interstitial lung disease (PH-ILD); Orenitram, a tablet dosage form of treprostinil to enhance the exercise capacity in PAH patients; Unituxin, a monoclonal antibody for treating high-risk neuroblastoma; and Adcirca, an oral PDE-5 inhibitor to enhance the exercise ability in PAH patients.

Further Reading

Analyst Recommendations for United Therapeutics (NASDAQ:UTHR)

Receive News & Ratings for United Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for United Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.